4.2 Review

miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma

期刊

PHARMACOGENOMICS
卷 18, 期 14, 页码 1341-1357

出版社

FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2017-0010

关键词

bile duct cancer; cholangiocarcinoma; diagnosis; liquid biopsy; miRNA; prediction; prognosis

资金

  1. Bennink Foundation
  2. Associazione Italiana per la Ricerca sul Cancro
  3. Tuscany Region 'Bando Fas Salute'
  4. No Surrender Cancer Trust
  5. Action Against Cancer
  6. CCA Foundation

向作者/读者索取更多资源

Cholangiocarcinoma (CCA) is a lethal malignancy originating from the biliary tract epithelium. Most patients are diagnosed at an advanced stage. Even after resection with curative intent, prognosis remains poor. Previous studies have reported the evolving role of miRNAs as novel biomarkers in cancer diagnosis, prognostication and chemotherapy response. Various miRNAs, such as miR-21, miR-26, miR-122 and miR-150, have been identified as possible blood-based biomarkers for noninvasive diagnosis of CCA. Moreover, epithelial-mesenchymal transition (EMT)-and angiogenesis-associated miRNAs have been implicated in tumor cell dissemination and are able to determine clinical outcome. In fact, miRNAs involved in cell survival might even determine chemotherapy response. This review provides an overview of known miRNAs as CCA-specific biomarkers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据